A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

被引：0

作者：

Borghaei, Hossein

Lynch, Thomas James

Rizvi, Naiyer A.

Chow, Laura Quan Man

Reilly, Robert

Crino, Lucio

Buyse, Marc E.

Ezzeddine, Rana

Lestini, Brian Joseph

Brahmer, Julie R.

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] St Mary Hosp, Langhorne, PA USA

[6] Azienda Osped Perugia, Perugia, Italy

[7] Int Inst Drug Dev, Louvain, Belgium

[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[9] Bristol Myers Squibb Co, Princeton, NJ USA

[10] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8122

引用

页数：2

共 50 条

[31] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
Michael A Postow
Diana M Cardona
Janis M Taube
Robert A Anders
Clive R Taylor
Jedd D Wolchok
Margaret K Callahan
Michael A Curran
Alexander M Lesokhin
Joseph F Grosso
Christine E Horak
John Cogswell
Jason S Simon
Ashok K Gupta
Mario Sznol
Journal of Translational Medicine, 12 (Suppl 1)
[32] A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)
Rizvi, Naiyer A.
Antonia, Scott J.
Chow, Laura Quan Man
Brahmer, Julie R.
Juergens, Rosalyn A.
Borghaei, Hossein
Shepherd, Frances A.
Laurie, Scott Andrew
Gerber, David E.
Goldman, Jonathan Wade
Shen, Yun
Harbison, Christopher
Alaparthy, Suresh
Chen, Allen C.
Gettinger, Scott N.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
Wolchok, Jedd D.
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Reed, Kathleen
Burke, Matthew M.
Caldwell, Anne
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Horak, Christine E.
Korman, Alan J.
Wigginton, Jon M.
Gupta, Ashok Kumar
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[34] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Gettinger, Scott N.
Horn, Leora
Gandhi, Leena
Spigel, David R.
Antonia, Scott J.
Rizvi, Naiyer A.
Powderly, John D.
Heist, Rebecca S.
Carvajal, Richard D.
Jackman, David M.
Sequist, Lecia V.
Smith, David C.
Leming, Philip
Carbone, David P.
Pinder-Schenck, Mary C.
Topalian, Suzanne L.
Hodi, F. Stephen
Sosman, Jeffrey A.
Sznol, Mario
McDermott, David F.
Pardoll, Drew M.
Sankar, Vindira
Ahlers, Christoph M.
Salvati, Mark
Wigginton, Jon M.
Hellmann, Matthew D.
Kollia, Georgia D.
Gupta, Ashok K.
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2004 - U32
[35] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
Hamanishi, Junzo
Mandai, Masaki
Ikeda, Takafumi
Minami, Manabu
Kawaguchi, Atsushi
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Yamaguchi, Ken
Ueda, Akihiko
Kanai, Masashi
Mori, Yukiko
Matsumoto, Shigemi
Murayama, Toshinori
Chikuma, Shunsuke
Morita, Satoshi
Yokode, Masayuki
Shimizu, Akira
Honjo, Tasuku
Konishi, Ikuo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)
Hodi, F. S.
Topalian, S. L.
Brahmer, J. R.
McDermott, D. F.
Smith, D. C.
Gettinger, S.
Taube, J. M.
Pardoll, D. M.
Wigginton, J. M.
Sznol, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
[37] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
Sznol, M.
Callahan, M. K.
Kluger, H.
Postow, M. A.
Burke, M.
Hong, Q.
Selby, M.
Korman, A.
Gupta, A.
Wolchok, J. D.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
[38] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Yamamoto, N.
Yamada, Y.
Nokihara, H.
Asahina, H.
Shibata, T.
Tamura, Y.
Seki, Y.
Honda, K.
Tanabe, Y.
Tamura, T.
ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
[39] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
Topalian, Suzanne Louise
Sznol, Mario
Brahmer, Julie R.
McDermott, David F.
Smith, David C.
Gettinger, Scott N.
Taube, Janis M.
Drake, Charles G.
Pardoll, Drew M.
Powderly, John D.
Carvajal, Richard D.
Sosman, Jeffrey Alan
Atkins, Michael B.
Antonia, Scott J.
Spigel, David R.
Lawrence, Donald P.
Kollia, Georgia
Gupta, Ashok Kumar
Wigginton, Jon M.
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
Hodi, F. Stephen
Baudelet, Christine
Chen, Allen C.
Weber, Jeffrey S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →